Navigation Links
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

ments:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. United Therapeutics Reports Third Quarter 2008 Financial Results
4. Arete Therapeutics Bolsters Management Team
5. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
10. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
11. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... executives from clinical trial marketing firm BBK Worldwide will lead ... Clinical Trials 2014 , to be held at the Hyatt ... Patient recruitment experts Bonnie A. Brescia , Matthew ... on the benefits of employing an effective patient engagement strategy, ... mobile apps – can be used to drive study participation ...
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 PrimeSource ... construction materials, selected SoundConnect to support ... cloud based audio and web conferencing platform GlobalMeet ... support PrimeSource’s employees’ needs. SoundConnect delivers award ... , PrimeSource Building Products will be utilizing ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised ... secured Otter Capital as a significant new partner. Otter ... GGI’s Agriplier™ technology, building on recent compelling field trial ... first meeting, we have been impressed with Otter Capital’s ... Alan Sobba, President and CEO of GGI. “We look ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
(Date:8/27/2014)... Orange, NJ. August 27, 2014. Using functional near ... differential brain activation patterns between people with multiple ... first MS study in which brain activation was ... task. The article, "Neuroimaging and cognition using functional ... published online on June 11 by Brain ...
(Date:8/27/2014)... N.C. -- Duke University researchers have identified a gene ... called OSCA1, encodes a protein in the cell membrane ... adjusts the plant,s water conservation machinery accordingly. , ... associate professor of biology at Duke. , The ... Nature , could make it easier to feed the ...
Breaking Biology News(10 mins):Nanodiamonds are forever 2Nanodiamonds are forever 3Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Water 'thermostat' could help engineer drought-resistant crops 2
... American Heart Association has pledged $50,000 to fund the ... engineering undergraduate students who are working to develop a ... from the Nintendo Wii video game console. Students ... began work on the project as seniors at UAB. ...
... This release is available in German ... in hospitals in particular are often caused by bacteria ... colonies of Pseudomonas aeruginosa produce virulence factors and can ... antibiotics from penetrating. The process of quorum sensing, which ...
... NY) Scientists at Albert Einstein College of Medicine ... predicting whether microbicides against HIV are safe for human ... "safe" microbicides made women more susceptible to HIV infection. ... the Journal of Infectious Disease . For ...
Cached Biology News:UAB students' Nintendo Wii CPR earns American Heart Association support 2A matter of density, not quantity 2New lab test offers better prediction of HIV microbicide safety 2New lab test offers better prediction of HIV microbicide safety 3